ID   NT2-D1
AC   CVCL_3407
SY   NT2/D1; NT2D1; Nt2D1; NTERA-2 clone D1; NTERA2-cloneD1; NTERA-2 cl.D1; NTera2 cl.D1; NTERA-2cl.D1; NTera 2/cl.D1; NTERA-2/D1; NTera2/D1; NTERA2-D1; NTera-2D1; Ntera2/D1; NTERA2/D1; NTERA2D1; NTera2D1
DR   BTO; BTO:0000946
DR   CLO; CLO_0008207
DR   EFO; EFO_0005236
DR   CLDB; cl3740
DR   CLDB; cl5088
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1973
DR   BCRC; 60356
DR   BCRJ; 0303
DR   CCLE; NTERA2CLD1_TESTIS
DR   Cell_Model_Passport; SIDM01203
DR   ChEMBL-Cells; CHEMBL3307482
DR   ChEMBL-Targets; CHEMBL614206
DR   Cosmic; 687052
DR   Cosmic; 908454
DR   Cosmic; 1995598
DR   Cosmic; 2077191
DR   Cosmic; 2163756
DR   Cosmic-CLP; 908454
DR   DepMap; ACH-002291
DR   ECACC; 01071221
DR   ENCODE; ENCBS374ENC
DR   ENCODE; ENCBS578HFO
DR   ENCODE; ENCBS631LTU
DR   ENCODE; ENCBS810EWQ
DR   FCS-free; 172-2-320-1-3-3
DR   GDSC; 908454
DR   GEO; GSM824855
DR   GEO; GSM824856
DR   GEO; GSM1040297
DR   GEO; GSM1040367
DR   GEO; GSM1670285
DR   ICLC; HTL97025
DR   IZSLER; BS TCL 204
DR   LINCS_LDP; LCL-1901
DR   Lonza; 1094
DR   PharmacoDB; NTERASclD1_1169_2019
DR   Wikidata; Q54931100
RX   PubMed=3293662;
RX   PubMed=6144603;
RX   PubMed=6694356;
RX   PubMed=8411264;
RX   PubMed=23325432;
RX   PubMed=24812411;
RX   PubMed=25802994;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   https://en.wikipedia.org/wiki/NTERA-2
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/NT2-D1_protocol.pdf
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/n/cell-lines-detail-113.html
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K9ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.78%; Native American=0%; East Asian, North=0.45%; East Asian, South=1.42%; South Asian=4.09%; European, North=53.03%; European, South=39.23% (PubMed=30894373).
CC   Misspelling: NTERA-S-cl-D1; In Cosmic 1995598.
CC   Misspelling: NTL-D1; In Cosmic 2077191.
CC   Misspelling: NT2101; In PubMed=24812411 and Cosmic 2163756.
CC   Derived from metastatic site: Lung.
ST   Source(s): ATCC; Cosmic-CLP; ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 11,12,13
ST   D5S818: 9,12
ST   D7S820: 10,12
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 18,19
DI   NCIt; C3752; Embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0034 ! NTERA-2
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 30
//
RX   PubMed=3293662; DOI=10.1016/0304-419X(88)90003-0;
RA   Andrews P.W.;
RT   "Human teratocarcinomas.";
RL   Biochim. Biophys. Acta 948:17-36(1988).
//
RX   PubMed=6144603; DOI=10.1016/0012-1606(84)90316-6;
RA   Andrews P.W.;
RT   "Retinoic acid induces neuronal differentiation of a cloned human
RT   embryonal carcinoma cell line in vitro.";
RL   Dev. Biol. 103:285-293(1984).
//
RX   PubMed=6694356;
RA   Andrews P.W., Damjanov I., Simon D., Banting G.S., Carlin C.R.,
RA   Dracopoli N.C., Fogh J.;
RT   "Pluripotent embryonal carcinoma clones derived from the human
RT   teratocarcinoma cell line Tera-2. Differentiation in vivo and in
RT   vitro.";
RL   Lab. Invest. 50:147-162(1984).
//
RX   PubMed=8411264; DOI=10.1002/jnr.490350603;
RA   Pleasure S.J., Lee V.M.-Y.;
RT   "NTera 2 cells: a human cell line which displays characteristics
RT   expected of a human committed neuronal progenitor cell.";
RL   J. Neurosci. Res. 35:585-602(1993).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=24812411; DOI=10.1158/1078-0432.CCR-13-2868;
RA   Feldman D.R., Iyer G., Van Alstine L., Patil S., Al-Ahmadie H.,
RA   Reuter V.E., Bosl G.J., Chaganti R.S.K., Solit D.B.;
RT   "Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but
RT   not BRAF in cisplatin-resistant germ cell tumors.";
RL   Clin. Cancer Res. 20:3712-3720(2014).
//
RX   PubMed=25802994; DOI=10.1177/026119291504300105;
RA   Jasnic-Savovic J., Klajn A., Milivojevic M., Mojsin M., Nikcevic G.;
RT   "Human embryonal carcinoma cells in serum-free conditions as an in
RT   vitro model system of neural differentiation.";
RL   Altern. Lab. Anim. 43:9-18(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//